Understand the source comparison
PCOS Peptide Ranking: Evidence-Based Comparison
Tirzepatide Dual GLP-1/GIP agonist. Enhances insulin secretion + peripheral glucose uptake 20.9% (SURMOUNT-1, 15mg weekly) HOMA-IR reduced 45% by week 20; fasting insulin down 38% Free androgen index reduced 28% by week 24 (independent of weight loss) Weekly s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- Dual GLP-1/GIP agonist. Enhances insulin secretion + peripheral glucose uptake
- 20.9% (SURMOUNT-1, 15mg weekly)
- HOMA-IR reduced 45% by week 20; fasting insulin down 38%
- Free androgen index reduced 28% by week 24 (independent of weight loss)
- Weekly subcutaneous injection
- Highest efficacy for both weight loss and direct androgen reduction. Preferred when budget allows
- Semaglutide
- Selective GLP-1 agonist. Slows gastric emptying, reduces glucagon, suppresses appetite centrally
- 14.9% (STEP-1, 2.4mg weekly)
- HOMA-IR improved 35% by week 12; visceral fat volume down 27%
- Free androgen index reduced 18–22% by week 24 (mediated by visceral fat loss)
- Best balance of efficacy, cost, and tolerability for PCOS weight loss studies
- Liraglutide
- First-generation GLP-1 agonist. Daily dosing, shorter half-life
- 5–8% (SCALE trials, 1.8–3.0mg daily)
- HOMA-IR improved 20–25% by week 16; less pronounced visceral fat reduction
- Improved menstrual regularity in 48% of anovulatory patients; androgen reduction modest
- Daily subcutaneous injection
- Lower cost option with proven PCOS-specific benefits; less weight loss than weekly agonists